MX2020005430A - Ligandos de psma para la formacion de imagenes y endorradioterapia. - Google Patents
Ligandos de psma para la formacion de imagenes y endorradioterapia.Info
- Publication number
- MX2020005430A MX2020005430A MX2020005430A MX2020005430A MX2020005430A MX 2020005430 A MX2020005430 A MX 2020005430A MX 2020005430 A MX2020005430 A MX 2020005430A MX 2020005430 A MX2020005430 A MX 2020005430A MX 2020005430 A MX2020005430 A MX 2020005430A
- Authority
- MX
- Mexico
- Prior art keywords
- endoradiotherapy
- imaging
- psma
- psma ligands
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nuclear Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente divulgación se refiere a la formación de imágenes y endorradioterapia de enfermedades que implican antígeno de membrana específico de próstata (PSMA). Se proporcionan compuestos que unen o inhiben PSMA y adicionalmente llevan al menos una fracción que es susceptible de radiomarcaje. También se porporcionan usos médicos de dichos compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17206510 | 2017-12-11 | ||
| PCT/EP2018/084399 WO2019115547A1 (en) | 2017-12-11 | 2018-12-11 | Psma ligands for imaging and endoradiotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020005430A true MX2020005430A (es) | 2020-08-27 |
Family
ID=60654872
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005430A MX2020005430A (es) | 2017-12-11 | 2018-12-11 | Ligandos de psma para la formacion de imagenes y endorradioterapia. |
| MX2023005053A MX2023005053A (es) | 2017-12-11 | 2020-07-13 | Ligandos de psma para la formacion de imagenes y endorradioterapia. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005053A MX2023005053A (es) | 2017-12-11 | 2020-07-13 | Ligandos de psma para la formacion de imagenes y endorradioterapia. |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US11497819B2 (es) |
| EP (3) | EP4464341A3 (es) |
| JP (3) | JP7317375B2 (es) |
| KR (1) | KR102815791B1 (es) |
| CN (2) | CN116617421A (es) |
| AU (2) | AU2018382479B2 (es) |
| BR (1) | BR112020011727A2 (es) |
| CA (1) | CA3078104A1 (es) |
| CL (1) | CL2020001542A1 (es) |
| CR (1) | CR20200241A (es) |
| CU (1) | CU24677B1 (es) |
| CY (1) | CY1125376T1 (es) |
| DK (2) | DK3723815T3 (es) |
| EC (1) | ECSP20029142A (es) |
| ES (2) | ES2997266T3 (es) |
| FI (1) | FI4008359T3 (es) |
| HR (2) | HRP20220764T1 (es) |
| HU (2) | HUE059083T2 (es) |
| IL (3) | IL313103B2 (es) |
| JO (1) | JOP20200135A1 (es) |
| LT (2) | LT3723815T (es) |
| MX (2) | MX2020005430A (es) |
| NZ (1) | NZ763033A (es) |
| PE (1) | PE20210456A1 (es) |
| PL (1) | PL3723815T3 (es) |
| PT (2) | PT3723815T (es) |
| RS (2) | RS66086B1 (es) |
| SG (1) | SG11202002965WA (es) |
| SI (2) | SI3723815T1 (es) |
| SM (1) | SMT202400439T1 (es) |
| TN (1) | TN2020000072A1 (es) |
| UA (1) | UA126413C2 (es) |
| WO (1) | WO2019115547A1 (es) |
| ZA (1) | ZA202003472B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4424378A3 (en) * | 2017-07-28 | 2024-12-11 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| LT3723815T (lt) | 2017-12-11 | 2022-07-25 | Technische Universität München | Psma ligandai, skirti vizualizavimui ir endoradioterapijai |
| CA3128406A1 (en) * | 2019-01-30 | 2020-08-06 | Technische Universitat Munchen | Cancer diagnostic imaging agents |
| ES2953196T3 (es) * | 2019-01-30 | 2023-11-08 | Univ Muenchen Tech | Radiotrazador de modo dual de unión a PSMA y terapéutico |
| JP7618599B2 (ja) | 2019-06-21 | 2025-01-21 | プロビンシャル・ヘルス・サービシーズ・オーソリティ | 前立腺特異的膜抗原を標的とする放射性標識化合物 |
| CN112321673B (zh) * | 2020-11-04 | 2022-09-20 | 北京市肿瘤防治研究所 | 一种前列腺特异性膜抗原靶向抑制剂及应用和探针 |
| CN113354707A (zh) * | 2021-06-07 | 2021-09-07 | 苏州思萃同位素技术研究所有限公司 | 一种针对前列腺癌的三功能诊疗一体化药物前体的合成方法及其产品 |
| WO2023173074A2 (en) * | 2022-03-10 | 2023-09-14 | The Research Foundation For The State University Of New York | Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment |
| CN115010629B (zh) * | 2022-06-07 | 2024-02-23 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用 |
| WO2025022285A2 (en) | 2023-07-21 | 2025-01-30 | Novartis Ag | Psma-targeting radioligand treatment regimen |
| WO2025029963A1 (en) | 2023-07-31 | 2025-02-06 | Curium Us Llc | [ 177lu] lutetium-psma i&t composition and dosimetry, kit, method of making, and method of using thereof |
| WO2025147677A1 (en) * | 2024-01-05 | 2025-07-10 | Point Biopharma, Inc. | Preparation of psma-targeted radiopharmaceutical |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1888581A2 (en) | 2005-05-16 | 2008-02-20 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
| RU2494096C2 (ru) * | 2008-08-01 | 2013-09-27 | Дзе Джонс Хопкинс Юниверсити | Агенты, связывающиеся с psma, и их применение |
| WO2010135431A2 (en) * | 2009-05-19 | 2010-11-25 | The Regents Of The University Of California | Compositions, devices, and methods related to prostate-specific membrane antigen |
| WO2015055318A1 (en) * | 2013-10-18 | 2015-04-23 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3536345A1 (en) | 2014-05-06 | 2019-09-11 | The Johns Hopkins University | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| HUE065327T2 (hu) | 2016-03-22 | 2024-05-28 | Univ Johns Hopkins | Prosztata-fajlagos membrán antigénhez célzott nagy affinitású szerek prosztatarák endoradioterápiájához |
| LT3723815T (lt) | 2017-12-11 | 2022-07-25 | Technische Universität München | Psma ligandai, skirti vizualizavimui ir endoradioterapijai |
| TW201930265A (zh) | 2017-12-11 | 2019-08-01 | 西班牙商阿爾米雷爾有限公司 | 作為acc抑制劑的吡咯衍生物 |
| EA202091402A1 (ru) | 2017-12-11 | 2020-09-01 | Хелсинн Хелскеа Са | Фумарат (r)-3-(1-(2,3-дихлор-4-(пиразин-2-ил)фенил)-2,2,2-трифторэтил)-1-метил-1-(1-метилпиперидин-4-ил)мочевины, способы его получения и применения |
-
2018
- 2018-12-11 LT LTEPPCT/EP2018/084399T patent/LT3723815T/lt unknown
- 2018-12-11 PT PT188122154T patent/PT3723815T/pt unknown
- 2018-12-11 DK DK18812215.4T patent/DK3723815T3/da active
- 2018-12-11 ES ES21218180T patent/ES2997266T3/es active Active
- 2018-12-11 TN TNP/2020/000072A patent/TN2020000072A1/en unknown
- 2018-12-11 US US16/765,729 patent/US11497819B2/en active Active
- 2018-12-11 CA CA3078104A patent/CA3078104A1/en active Pending
- 2018-12-11 CR CR20200241A patent/CR20200241A/es unknown
- 2018-12-11 PT PT212181804T patent/PT4008359T/pt unknown
- 2018-12-11 DK DK21218180.4T patent/DK4008359T3/da active
- 2018-12-11 JO JOP/2020/0135A patent/JOP20200135A1/ar unknown
- 2018-12-11 JP JP2020526146A patent/JP7317375B2/ja active Active
- 2018-12-11 RS RS20241176A patent/RS66086B1/sr unknown
- 2018-12-11 AU AU2018382479A patent/AU2018382479B2/en active Active
- 2018-12-11 EP EP24198677.7A patent/EP4464341A3/en active Pending
- 2018-12-11 UA UAA202003533A patent/UA126413C2/uk unknown
- 2018-12-11 ES ES18812215T patent/ES2914832T3/es active Active
- 2018-12-11 CN CN202310801735.3A patent/CN116617421A/zh active Pending
- 2018-12-11 MX MX2020005430A patent/MX2020005430A/es unknown
- 2018-12-11 CN CN201880056196.2A patent/CN111182927B/zh active Active
- 2018-12-11 RS RS20220527A patent/RS63279B1/sr unknown
- 2018-12-11 SI SI201830691T patent/SI3723815T1/sl unknown
- 2018-12-11 HU HUE18812215A patent/HUE059083T2/hu unknown
- 2018-12-11 IL IL313103A patent/IL313103B2/en unknown
- 2018-12-11 BR BR112020011727-7A patent/BR112020011727A2/pt unknown
- 2018-12-11 SI SI201831155T patent/SI4008359T1/sl unknown
- 2018-12-11 WO PCT/EP2018/084399 patent/WO2019115547A1/en active IP Right Grant
- 2018-12-11 KR KR1020207014036A patent/KR102815791B1/ko active Active
- 2018-12-11 SG SG11202002965WA patent/SG11202002965WA/en unknown
- 2018-12-11 SM SM20240439T patent/SMT202400439T1/it unknown
- 2018-12-11 PE PE2020000552A patent/PE20210456A1/es unknown
- 2018-12-11 LT LTEP21218180.4T patent/LT4008359T/lt unknown
- 2018-12-11 CU CU2020000052A patent/CU24677B1/es unknown
- 2018-12-11 FI FIEP21218180.4T patent/FI4008359T3/fi active
- 2018-12-11 EP EP21218180.4A patent/EP4008359B1/en active Active
- 2018-12-11 EP EP18812215.4A patent/EP3723815B1/en active Active
- 2018-12-11 IL IL319022A patent/IL319022A/en unknown
- 2018-12-11 IL IL274072A patent/IL274072B2/en unknown
- 2018-12-11 NZ NZ763033A patent/NZ763033A/en unknown
- 2018-12-11 HU HUE21218180A patent/HUE069034T2/hu unknown
- 2018-12-11 HR HRP20220764TT patent/HRP20220764T1/hr unknown
- 2018-12-11 HR HRP20241453TT patent/HRP20241453T1/hr unknown
- 2018-12-11 PL PL18812215.4T patent/PL3723815T3/pl unknown
-
2020
- 2020-06-03 EC ECSENADI202029142A patent/ECSP20029142A/es unknown
- 2020-06-10 CL CL2020001542A patent/CL2020001542A1/es unknown
- 2020-06-10 ZA ZA2020/03472A patent/ZA202003472B/en unknown
- 2020-07-13 MX MX2023005053A patent/MX2023005053A/es unknown
-
2022
- 2022-07-15 US US17/866,034 patent/US20230122957A1/en active Pending
- 2022-07-20 CY CY20221100496T patent/CY1125376T1/el unknown
-
2023
- 2023-07-11 JP JP2023113523A patent/JP7572080B2/ja active Active
-
2024
- 2024-10-03 JP JP2024173980A patent/JP2025011169A/ja active Pending
-
2025
- 2025-02-07 AU AU2025200837A patent/AU2025200837A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005053A (es) | Ligandos de psma para la formacion de imagenes y endorradioterapia. | |
| ZA201906832B (en) | Novel psma-binding agents and uses thereof | |
| EA201890131A1 (ru) | Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38 | |
| PH12020551443A1 (en) | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease | |
| EA201791485A1 (ru) | Анти-cd47-антитела и их применения | |
| EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| EA201890857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| EA201691323A1 (ru) | Анти-vista антитела и фрагменты | |
| EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
| MA40682A (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| EA201892430A1 (ru) | Синтез индазолов | |
| EA201691487A1 (ru) | Антитела человека к pd-l1 | |
| MA34057B1 (fr) | Compositions et methodes pour le diagnostic et le traitement d'une tumeur | |
| EA201791050A1 (ru) | Конъюгаты антител и лекарственных средств | |
| EA201691541A1 (ru) | Новые анти-baff антитела | |
| EA201692100A1 (ru) | Новые антитела против rnf43 и способы их применения | |
| EA201691141A1 (ru) | Соединения против ccr6 | |
| MA38986B1 (fr) | Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate | |
| GEP20207106B (en) | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer | |
| MX380550B (es) | Sintesis de indazoles. | |
| EA201790400A1 (ru) | Зонды для визуализации белка хантингтина | |
| SV2019005838A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| EA201992317A1 (ru) | Композиции и способы для диагностики рака легких | |
| JOP20150008B1 (ar) | أجسام مضادة ل vista وأجزاء منها | |
| EA201690294A1 (ru) | Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов |